Aclaris Therapeutics (ACRS) Reports Q4 Loss of $0.28/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Wall St set to open higher as jobs data dampens rate hike odds, yields fall
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- Wells Fargo names 13 stocks as overweight tactical ideas
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2015 Operating and Financial Results
March 23, 2016 4:01 PM EDTMALVERN, Pa., March 23, 2016 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage specialty pharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2015 and provided an update on its clinical development programs. Â Â Â Â
It has been an exciting time for Aclaris since our IPO in October of last year as we have made significant progress with the advancement of our development pipeline. With our lead drug candidate, A-101, in the clinic for two indications (seborrheic keratosis and common warts), we look forward to seeing the results which... More
